Palatin Technologies (NYSE:PTN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Palatin Technologies (NYSE:PTNFree Report) in a research report report published on Friday morning. The firm issued a sell rating on the stock.

Palatin Technologies Stock Down 10.6 %

Shares of PTN opened at $0.22 on Friday. The company has a market capitalization of $5.72 million, a PE ratio of -0.14 and a beta of 0.89.

Palatin Technologies Company Profile

(Get Free Report)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

See Also

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.